Biosenic (FRA:BT1) Pre-Tax Income

: €-23.59 Mil (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. Biosenic's pretax income for the six months ended in Jun. 2023 was €-21.06 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2023 was €-23.59 Mil. Biosenic's pretax margin was %.

During the past 10 years, Biosenic's highest Pretax Margin was -1401.10%. The lowest was -30709.76%. And the median was -1575.40%.

Biosenic Pre-Tax Income Historical Data

The historical data trend for Biosenic's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Pre-Tax Income

-14.01

-7.52

-15.75

-0.98

-3.05

Biosenic Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Pre-Tax Income																-6.07	5.09	-0.53	-2.52	-21.06

Competitive Comparison

For the Biotechnology subindustry, Biosenic's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosenic Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, Biosenic's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Biosenic's Pre-Tax Income falls into.

Biosenic Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Biosenic's Pretax Income for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.318	+	0	+	-0.278	+	0.003	+	-0.456
	=	-3.05

Biosenic's Pretax Income for the quarter that ended in Jun. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.901	+	0	+	-1.136	+	0.03	+	-16.056
	=	-21.06

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-23.59 Mil.

Biosenic (FRA:BT1) Pre-Tax Income Explanation

Biosenic's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-21.063	/	0
	=	%

During the past 10 years, Biosenic's highest Pretax Margin was -1401.10%. The lowest was -30709.76%. And the median was -1575.40%.

Biosenic Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Biosenic's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenic (FRA:BT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (FRA:BT1) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

BIOS:Belgium

Address

Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, Gosselies, BEL, 1435

Website

https://www.biosenic.com

Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic (FRA:BT1) Headlines

No Headlines